More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Last month (June 2021), India’s Department of Pharmaceuticals issued operational guidelines for the country’s new production-linked incentive (PLI) scheme for starting materials, intermediates, and APIs. The PLI scheme is intended to increase...

At the halfway point in 2021, how are approvals of new molecular entities (NMEs) by the FDA progressing, and how does it compare to prior years? What NMEs have been approved, and what was the mix between small molecules and biologics? And, are...

ICROM and PolyCrystalLine SpA announce their strategic and exclusive partnership to provide integrated solutions for chemical development and custom manufacturing of APIs.

Mergers and acquisition in the pharmaceutical and life-sciences sector have been a mixed bag in the first half of 2021. The total value and number of deals increased exponentially compared to mid-year 2020 levels, but there have been no mega deals...

The COVID-19 pandemic gave rise to innovation in conducting clinical trials, including decentralized and direct-to-patient services. Will this trend continue, and what may be the impact on clinical trial material supply? DCAT Value Chain Insights...